RxDoctor Payments Data

Patrick Grace, MD

Pain Medicine · Bismarck, NDNPI 1447698469

Payments from drug & device makers

What this record shows

It is spread thinly across 26 manufacturers, the largest accounting for just 22.5%. Reporting peaked in 2019 at $4,845 and has fallen 84.5% since, to $753 in 2025.

$13,798in general payments, 2019–2025

Across 246 payments — averaging $56.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vertos Medical, Inc.$3K
  • Abbott$3K
  • Nevro Corp.$3K
  • Si-bone, Inc.$1K
  • Pacira Pharmaceuticals Incorporated$977
  • AbbVie$857
  • plus $3K from 20 others
$1,025in research payments, 2019–2025

Across 1 payment — averaging $1025.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$1K

What the payments were for

  • Travel & lodging$6,35946%
  • Food & beverage$7,44054%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few pain medicine providers in North Dakotato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$211,548
Medicare patients
473
Services billed
2,662

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cephalexin31$166

Paid to pharmacies, not to this prescriber.

Other pain medicine in Bismarck

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →